https://www.live-feeds.com/feed/moderna-swings-to-profit-lifts-outlook-as-covid-19-vaccine-demand-stabilizesContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/moderna-swings-to-profit-lifts-outlook-as-covid-19-vaccine-demand-stabilizeshttps://www.live-feeds.com/feed/moderna-swings-to-profit-lifts-outlook-as-covid-19-vaccine-demand-stabilizes#u193233Wed, 11 Nov 2026 06:47:06 +0000Moderna reported a third-quarter profit and lifted its full-year 2026 revenue forecast, citing stabilizing demand for its Covid-19 vaccine overseas and early traction for newer respiratory and cancer vaccines. The biotech company topped analyst estimates for both earnings and revenue in the quarter. Chief Executive Stephane Bancel said the updated Covid shot is gaining market share internationally, while the pipeline, including a personalized cancer vaccine developed with Merck, is advancing toward key data readouts. Investors have driven the stock to a five-year high largely on oncology optim